Cost Effectiveness Evaluation Of Apixaban, Dabigatran Rivaroxaban And Warfarin For Prevention Of Tromboembolism In Patients With Atrial Fibrillation In Trinidad And Tobago
May 1, 2014, 00:00
10.1016/j.jval.2014.03.678
https://www.valueinhealthjournal.com/article/S1098-3015(14)00729-3/fulltext
Title :
Cost Effectiveness Evaluation Of Apixaban, Dabigatran Rivaroxaban And Warfarin For Prevention Of Tromboembolism In Patients With Atrial Fibrillation In Trinidad And Tobago
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00729-3&doi=10.1016/j.jval.2014.03.678
First page :
A116
Section Title :
Cardiovascular Disorders
Open access? :
No
Section Order :
110